MGEN News and Press, Miragen Therapeutics Inc. From 12/11/19

Aimed at delivering key milestones next year, Miragen (NASDAQ: MGEN ) announces major changes in its strategy. Key points: More news on: Miragen Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Expecting topline data in Q3 2020 from truncated Phase 2 SOLAR clinical trial of cobomarsen in CTCL Pursuing guidance from FDA on a clinical development plan for cobomarsen in ATLL; anticipate meeting in Q2 2020 Focusing future pipeline efforts primarily on the development of MRG...

BOULDER, Colo., Nov. 26, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that management will be presenting at the Evercore ISI He...

miRagen Therapeutics, Inc. (MGEN) Q3 2019 Earnings Conference Call November 7, 2019 4:30 PM ET Company Participants Dan Ferry – Managing Director of LifeSci Advisors Bill Marshall – President and Chief Executive Officer Jason Leverone – Chief Financial Office...

Miragen Therapeutics (NASDAQ: MGEN ): Q3 GAAP EPS of -$0.36 misses by $0.06 . More news on: Miragen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Announced positive data from two Phase 1 clinical trials of MRG-110 Remain on track to announce interim top-line data from its Phase 2 clinical trial of remlarsen in keloids by year end Implemented restructuring to focus resources primarily on the development of cobomarsen and micr...

An overview of its second-generation miR-29 mimics Clinical development of its microRNA inhibitors BOULDER, Colo., Oct. 28, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies ...

BOULDER, Colo., Oct. 22, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will host a conference call and webcast on Thursday, November 7 th , at 4...

MiRagen Therapeutics (NASDAQ: MGEN ) is up  25%  premarket after announcing new data from two Phase 1 clinical trials of MRG-110, a microRNA-92 inhibitor. More news on: Miragen Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Synlogic (NASDAQ: SYBX )  -25%  in reaction to its decision to terminate development of SYNB1020 for the treatment of hyperammonemia. More news on: Synlogic, Inc., Sarepta Therapeutics, Inc., Fabrinet, Stocks on the move, Read more ...